Mengyue Ren

Dr. Mengyue Ren


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
MRMengyue Ren
Mengyue Ren
QTQingfa Tang
Qingfa Tang
FCFeilong Chen
Feilong Chen
XXXuefeng Xing
Xuefeng Xing
YHYao Huang
Yao Huang
XTXiaomei Tan
Xiaomei Tan
Allergic rhinitis (AR) is one of the most common allergic diseases, which adversely affect patients’ quality of life. Mahuang Fuzi Xixin decoction (MFXD) has been widely used to treat AR in clinics in Asian countries. This study investigated the effect and possible therapeutic mechanisms of MFXD in the treatment of AR. A Wistar rat model of ovalbumin- (OVA-) induced AR was established and then treated with three doses of MFXD; AR symptoms, serum total immunoglobulin E, histamine, histopathological features, and release and expression of factors related to type 1 helper T (Th1) and type 2 helper T (Th2) responses were analyzed. Our study demonstrated that MFXD has a good therapeutic effect on OVA-induced allergic inflammation in an AR rat model as manifested in reduced frequencies of sneezing and nasal scratching and in reduced serum levels of total IgE and HIS. In addition, MFXD regulates imbalance in Th1/Th2 cells caused by AR by simultaneously attenuating Th1 and Th2 responses, such as by reducing the serum levels of IFN-γ and IL-4 and mRNA expression levels of IFN-γ, IL-4, GATA-3, and STAT-6. This study provided valuable information on the immunoregulatory effect of MFXD for the treatment of AR in future clinical studies.

13 February 2017 in Molecules
Verified
Journal Article
Open access
PDF file
MRMengyue Ren
Mengyue Ren
QYQing-Tian Yu
Qing-Tian Yu
CSChun-Yu Shi
Chun-Yu Shi
JLJiabo Luo
Jiabo Luo
Cancer is one of the most common lethal diseases, and natural products have been extensively studied as anticancer agents considering their availability, low toxicity, and economic affordability. Plants belonging to the genus Aconitum have been widely used medically in many Asian countries since ancient times. These plants have been proven effective for treating several types of cancer, such as lung, stomach, and liver cancers. The main effective components of Aconitum plants are diterpenoid alkaloids—which are divided into C18-, C19-, C20-, and bis-diterpenoid alkaloids—are reportedly some of the most promising, naturally abundant compounds for treating cancer. This review focuses on the progress of diterpenoid alkaloids with different structures derived from Aconitum plants and some of their derivatives with potential anticancer activities. We hope that this work can serve as a reference for further developing Aconitum diterpenoid alkaloids as anticancer agents.


1 May 2015 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
SSShuai Song
Shuai Song
FCFeilong Chen
Feilong Chen
XXXuefeng Xing
Xuefeng Xing
MRMengyue Ren
Mengyue Ren
QMQinhai Ma
Qinhai Ma
JLJiabo Luo
Jiabo Luo

25 May 2020 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
XLXiao Liang
Xiao Liang
CLChang-Shun Liu
Chang-Shun Liu
XWXiao-Han Wei
Xiao-Han Wei
TXTing Xia
Ting Xia
FCFei-Long Chen
Fei-Long Chen
XTXiaomei Tan
Xiaomei Tan
Mahuang Fuzi Xixin Decoction (MFXD), a Chinese traditional herbal formulation, has been used to treat allergic rhinitis (AR) in China for centuries. However, the mechanism underlying its effect on AR is unclear. This study investigated the mechanism underlying the therapeutic effects of MFXD on AR. Ovalbumin-induced AR rat models were established, which were then treated with MFXD for 14 days. Symptom scores of AR were calculated. The structure of the gut microbiota was analyzed by 16S rRNA gene sequencing and qPCR. Short-chain fatty acid (SCFA) content in rat stool and serum was determined by GC-MS. Inflammatory and immunological responses were assessed by histopathology, ELISA, flow cytometry, and western blotting. Our study demonstrated that MFXD reduced the symptom scores of AR and serum IgE and histamine levels. MFXD treatment restored the diversity of the gut microbiota: it increased the abundance of Firmicutes and Bacteroidetes and decreased the abundance of Proteobacteria and Cyanobacteria. MFXD treatment also increased SCFA content, including that of acetate, propionate, and butyrate. Additionally, MFXD administration downregulated the number of Th17 cells and the levels of the Th17-related cytokines IL-17 and RORγt. By contrast, there was an increase in the number of Treg cells and the levels of the Treg-related cytokines IL-10 and Foxp3. MFXD and butyrate increased the levels of ZO-1 in the colon. This study indicated MFXD exerts therapeutic effects against AR, possibly by regulating the gut microbial composition and Th17/Treg balance.

1 January 2017 in Journal of Immunology Research
Verified
Journal Article
Open access
DSDazhi Shi
Dazhi Shi
MXMengyi Xu
Mengyi Xu
MRMengyue Ren
Mengyue Ren
EPEnshan Pan
Enshan Pan
CLChaohua Luo
Chaohua Luo
QTQingfa Tang
Qingfa Tang
Objective. This study aimed to explore the immunoregulatory effect of flavonoids of blueberry (Vaccinium corymbosum L.) leaves (FBL). Methods. The flavonoids of blueberry leaves were prepared with 70% ethanol and were identified by ultraperformance liquid chromatography/quadrupole-time-of-flight mass spectrometry (UPLC/Q-Tof-MS). The immunoregulatory effect and possible regulatory mechanisms of FBL were investigated in lipopolysaccharide- (LPS-) induced RAW 264.7 cells. Results. According to the results of UPLC/Q-Tof-MS, nine flavonoids of blueberry leaves were identified. FBL showed a significant reduction in the production of TNF-α in LPS-stimulated RAW 264.7 cells. FBL significantly decreased the expression of NF-κB p65 and P-NF-κB p65 in LPS-induced RAW 264.7 cells in a dose-dependent manner. Conclusion. Our study showed the immunoregulatory effect of FBL through the suppression of TNF-α via the NF-κB signal pathway.